Get the Stockscreener App
212.22
0.10%
-0.21
After Hours:
212.22
Madrigal Pharmaceuticals Inc stock is traded at $212.22, with a volume of 471.25K.
It is down -0.10% in the last 24 hours and down -14.13% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$212.43
Open:
$211.6
24h Volume:
471.25K
Relative Volume:
1.73
Market Cap:
$4.60B
Revenue:
-
Net Income/Loss:
$-510.45M
P/E Ratio:
-11.03
EPS:
-19.24
Net Cash Flow:
$-455.82M
1W Performance:
-5.98%
1M Performance:
-14.13%
6M Performance:
-20.53%
1Y Performance:
+45.32%
1-Day Range:
$208.94
$218.74
1-Week Range:
$208.94
$227.21
52-Week Range:
$119.76
$299.98
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) - The Manila Times
Perceptive Advisors LLC Has $74.13 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra launch bolsters stock outlook By Investing.com - Investing.com UK
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Armistice Capital LLC Has $42.02 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Affinity Asset Advisors LLC - MarketBeat
Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? - Insider Monkey
Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? - Yahoo Finance
Mutual of America Capital Management LLC Has $3.18 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
10 Best Guru Stocks To Buy Now - Insider Monkey
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is Avoro Capital Advisors LLC’s 2nd Largest Position - Defense World
Tri Locum Partners LP Acquires 11,997 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Victory Capital Management Inc. - Defense World
Tri Locum Partners LP Purchases 11,997 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Ensign Peak Advisors Inc Has $23.36 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Zacks Research Equities Analysts Raise Earnings Estimates for McKesson Co. (NYSE:MCK) - Defense World
McKesson Co. (NYSE:MCK) Shares Bought by Heron Bay Capital Management - Defense World
McKesson Co. (NYSE:MCK) Stock Position Raised by Sei Investments Co. - Defense World
Oppenheimer Asset Management Inc. Invests $414,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to “Sell” by StockNews.com - Defense World
Michelle Madrigal wishes to have another baby soon - Inquirer.net
How the (MDGL) price action is used to our Advantage - Stock Traders Daily
State of New Jersey Common Pension Fund D Has $2.27 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
State of New Jersey Common Pension Fund D Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
XTX Topco Ltd Buys 1,383 Shares of McKesson Co. (NYSE:MCK) - Defense World
McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Mercer Global Advisors Inc. ADV Has $38.18 Million Stake in McKesson Co. (NYSE:MCK) - Defense World
Dimensional Fund Advisors LP Grows Stock Position in McKesson Co. (NYSE:MCK) - Defense World
Argent Trust Co Cuts Stock Holdings in McKesson Co. (NYSE:MCK) - Defense World
American Century Companies Inc. Boosts Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Sofinnova Investments Inc. Grows Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is AlpInvest Partners B.V.'s 6th Largest Position - MarketBeat
This Insider Has Just Sold Shares In Madrigal Pharmaceuticals - Simply Wall St
Rhumbline Advisers Has $7.10 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells $1,551,490.29 in Stock - Defense World
Principal Financial Group Inc. Has $856,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals CEO sells over $1.5m in stock - Investing.com India
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells $1,551,490.29 in Stock - MarketBeat
Madrigal Pharmaceuticals CEO sells over $1.5m in stock - Investing.com
TD Asset Management Inc Buys 5,400 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
TD Asset Management Inc Grows Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by StockNews.com to “Sell” - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by StockNews.com to "Sell" - MarketBeat
Emerald Advisers LLC Has $27.11 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Synta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus - Yahoo Finance
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report? - Yahoo Finance
Bank of New York Mellon Corp Has $20.68 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
How To Trade (MDGL) - Stock Traders Daily
Fiera Capital Corp Invests $32.34 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $343.83 Consensus Price Target from Brokerages - MarketBeat
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):